Komori
Share Issuance and Disposal4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions

No 13th stock acquisition rights were exercised in August 2026, and 0 shares were newly issued. As of the end of the month, 8,338 unexercised stock acquisition rights remained, unchanged from the end of the previous month.

Worth reading
45Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Number of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares)

発行済株式総数

Exercise ratio for the month under review: 0.00% (exercise ratio relative to the total number issued)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥80 or ¥81 (the respective exercise prices during the month under review). Initial exercise price and floor under the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: Not disclosed; unexercised balance as of the end of the month preceding the month under review: 8,338; unexercised balance as of the end of the month under review: 8,338
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financing
Timing 31 July 2025 / Type Issuance of the 13th Series Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares)
Dilution RateExercise ratio for the month under review: 0.00% (exercise ratio relative to the total number issued)
Total number of issued shares57,559,412 shares (as of the end of the month preceding the month under review) → Not disclosed
Exercise price¥80 or ¥81 (the respective exercise prices during the month under review). Initial exercise price and floor under the adjustment clause: Not disclosed
Number of Stock Acquisition RightsTotal number issued: Not disclosed; unexercised balance as of the end of the month preceding the month under review: 8,338; unexercised balance as of the end of the month under review: 8,338
Procedures under the Corporate Code of ConductThe disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financingTiming 31 July 2025 / Type Issuance of the 13th Series Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status for August 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori